Is Kardigan, Inc. (KARD) a Buy, Sell, or Hold?
NASDAQ : KARD
Kardigan, Inc.
$21.02 USD
-$0.97 (-4.41%)
- Volume
- 378.17K
- Average Volume
- 968.29K
- Market Capitalization
- $1.88B
- P/E Ratio
- Dividend Yield
- %
- Price Target
- $38.50
- Year High
- $27.00
- Year Low
- $16.25
- Day High
- —
- Day Low
- —
- Payout Ratio
- Current Ratio
| Source | Headline |
|---|---|
|
Kardigan Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)---- $KARD #Kardigan--Kardigan announced the closing of its initial public offering. businesswire.com - 2026-06-22 17:03:00 |
|
Kardigan rises in Nasdaq debut after upsized $400 million IPO
Kardigan's shares rose 1.6% in their Nasdaq debut on Thursday, after the heart drug developer raised $400 million in an upsized U.S. initial public offering. reuters.com - 2026-06-18 12:49:22 |
|
Kardigan Announces Pricing of Upsized Initial Public Offering
SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)---- $KARD #Kardigan--Kardigan™, Inc. (Nasdaq: KARD) (“Kardigan”), a clinical-stage precision therapeutics company developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist, today announced the pricing of its initial public offering of 25,000,000 shares of common stock at a public offering price of $16 per share. The gross proceeds from the offering are expected to be $400 million, before unde. businesswire.com - 2026-06-17 20:30:00 |
|
Heart drug developer Kardigan targets $1.4 billion valuation in US IPO
Kardigan is targeting a valuation of up to $1.4 billion in its initial public offering in the United States, the drug developer said on Thursday. reuters.com - 2026-06-11 06:33:30 |
|
Kardigan Begins Process For IPO On Cardiovascular Treatments Promise
Kardigan, Inc. (KARD) is a clinical-stage biopharma targeting various cardiovascular disease treatments with a pipeline led by Danicamtiv, now in Phase 2b/3 trials. KARD leverages its Prolario AI platform to optimize clinical trial design, patient identification, and data collection, aiming for improved outcomes and efficiency. The company is well-capitalized with $287 million in cash and strong backing from top-tier life science VCs, positioning it for robust pipeline advancement. seekingalpha.com - 2026-06-02 09:48:25 |
